Beam Therapeutics' ACCE composite score fell from 42 to 29. We break down what likely drove the move across growth, value, quality, and momentum.
What changed
$BEAM just saw its ACCE composite score fall 13 points, moving from 42 down to 29 out of 100. That is a meaningful single-step drop, and it puts the stock firmly in cautious territory on our scale. The current score breakdown reads: Growth 7, Value 10, Quality 31, Momentum 68.
The stock trades at $27.38 as of August 6, 2026, against an analyst consensus target of $52.23 — a gap that looks attractive on the surface, but the score move signals the underlying fundamentals deserve scrutiny before drawing conclusions from that spread.
What likely drove the move
A 13-point composite drop typically reflects deterioration across at least two or three subscores simultaneously. Looking at where $BEAM sits today, a few areas stand out as the probable culprits.
Growth (7/100) is the weakest pillar by a wide margin. A year-over-year revenue decline of -94.2% is an extreme contraction — the kind of number that reflects a collaboration payment, licensing deal, or milestone revenue that landed in a prior period and did not repeat. Clinical-stage biotech companies often see this pattern, but the scoring model treats it as a hard negative regardless of the cause. If this subscore deteriorated further in the latest update, it alone could account for a large share of the composite decline.
Value (10/100) is nearly as weak. With no positive earnings to anchor a P/E ratio, traditional valuation metrics produce little signal, and the FCF yield sits at -12.3%. The model has limited positive inputs to work with here, and any widening of cash burn relative to market cap would push this subscore lower.
Quality (31/100) is middling. A net margin of -55.5%, ROE of -8.2%, and an earnings quality flag marked "concerning" all weigh on this pillar. $BEAM also missed its most recent quarterly earnings estimate by 2.2% in Q3 FY2026. That miss, while not catastrophic, adds to a pattern that keeps the quality score from recovering.
Momentum (68/100) is the one bright spot and the reason the composite score is not lower. A 1-year return of +49.6% reflects genuine price strength, and momentum remains the stock's highest-scoring dimension. However, momentum subscores can shift quickly if price action softens, and a reversal there would put further pressure on an already-low composite.
What it means
The score drop to 29 reflects a stock where one strong dimension — price momentum — is doing most of the heavy lifting while growth, value, and quality all register weak readings. That combination warrants caution. The analyst target of $52.23 implies significant upside from current levels, but the ACCE model is flagging that the fundamental foundation supporting that target is thin right now.
For the full live data on $BEAM, visit acceinvestments.com/stocks/BEAM.
